Literature DB >> 28077497

Bone material strength index as measured by impact microindentation is altered in patients with acromegaly.

F Malgo1, N A T Hamdy1, T J Rabelink2, H M Kroon3, K M J A Claessen4, A M Pereira4, N R Biermasz4, N M Appelman-Dijkstra1.   

Abstract

OBJECTIVE: Acromegaly is a rare disease caused by excess growth hormone (GH) production by the pituitary adenoma. The skeletal complications of GH and IGF-1 excess include increased bone turnover, increased cortical bone mass and deteriorated microarchitecture of trabecular bone, associated with a high risk of vertebral fractures in the presence of relatively normal bone mineral density (BMD). We aimed to evaluate tissue-level properties of bone using impact microindentation (IMI) in well-controlled patients with acromegaly aged ≥18 years compared to 44 controls from the outpatient clinic of the Centre for Bone Quality. DESIGN AND METHODS: In this cross-sectional study, bone material strength index (BMSi) was measured in 48 acromegaly patients and 44 controls with impact microindentation using the osteoprobe.
RESULTS: Mean age of acromegaly patients (54% male) was 60.2 years (range 37.9-76.5), and 60.5 years (range 39.8-78.6) in controls (50% male). Patients with acromegaly and control patients had comparable BMI (28.2 kg/m2 ± 4.7 vs 26.6 kg/m2 ± 4.3, P = 0.087) and comparable BMD at the lumbar spine (1.04 g/cm2 ± 0.21 vs 1.03 g/cm2 ± 0.13, P = 0.850) and at the femoral neck (0.84 g/cm2 ± 0.16 vs 0.80 g/cm2 ± 0.09, P = 0.246). BMSi was significantly lower in acromegaly patients than that in controls (79.4 ± 0.7 vs 83.2 ± 0.7; P < 0.001).
CONCLUSION: Our data indicates that tissue-level properties of cortical bone are significantly altered in patients with controlled acromegaly after reversal of long-term exposure to pathologically high GH and IGF-1 levels. Our findings also suggest that methods other than DXA should be considered to evaluate bone fragility in patients with acromegaly.
© 2017 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28077497     DOI: 10.1530/EJE-16-0808

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  10 in total

1.  Direct effects of octreotide on osteoblast cell proliferation and function.

Authors:  E Vitali; E Palagano; M L Schiavone; G Mantovani; C Sobacchi; G Mazziotti; A Lania
Journal:  J Endocrinol Invest       Date:  2022-01-12       Impact factor: 4.256

Review 2.  Update on vertebral fractures in pituitary diseases: from research to clinical practice.

Authors:  Flaminia Carrone; Salvatore Ariano; Sara Piccini; Davide Milani; Marco Mirani; Luca Balzarini; Andrea Gerardo Lania; Gherardo Mazziotti
Journal:  Hormones (Athens)       Date:  2021-02-19       Impact factor: 2.885

3.  Treatments of osteoporosis increase bone material strength index in patients with low bone mass.

Authors:  M Schoeb; F Malgo; J J M Peeters; E M Winter; S E Papapoulos; N M Appelman-Dijkstra
Journal:  Osteoporos Int       Date:  2020-04-08       Impact factor: 4.507

4.  Feasibility and tolerability of bone impact microindentation testing: a cross-sectional, population-based study in Australia.

Authors:  Pamela Rufus-Membere; Kara L Holloway-Kew; Adolfo Diez-Perez; Mark A Kotowicz; Julie A Pasco
Journal:  BMJ Open       Date:  2018-12-22       Impact factor: 2.692

5.  3D DXA Hip Differences in Patients with Acromegaly or Adult Growth Hormone Deficiency.

Authors:  Luis Gracia-Marco; Sheila Gonzalez-Salvatierra; Antonia Garcia-Martin; Esther Ubago-Guisado; Beatriz Garcia-Fontana; José Juan Gil-Cosano; Manuel Muñoz-Torres
Journal:  J Clin Med       Date:  2021-02-09       Impact factor: 4.241

6.  Low sclerostin levels after long-term remission of acromegaly.

Authors:  Kim M J A Claessen; Iris C M Pelsma; Herman M Kroon; Antoon H van Lierop; Alberto M Pereira; Nienke R Biermasz; Natasha M Appelman-Dijkstra
Journal:  Endocrine       Date:  2021-08-26       Impact factor: 3.633

7.  Bone material strength index as measured by in vivo impact microindentation is normal in subjects with high-energy trauma fractures.

Authors:  M Schoeb; E M Winter; F Malgo; I B Schipper; R J P van der Wal; S E Papapoulos; N M Appelman-Dijkstra
Journal:  Osteoporos Int       Date:  2022-03-21       Impact factor: 5.071

8.  Bone tissue quality in patients with monoclonal gammopathy of uncertain significance.

Authors:  Guillermina Orduna; Leonardo Mellibovsky; Eugenia Abella; Xavier Nogués; Roser Granero; Natalia García-Giralt; Marta Pineda-Moncusí; Roberto Güerri-Fernández; Daniel Prieto-Alhambra; Adolfo Díez-Pérez
Journal:  J Bone Miner Metab       Date:  2020-01-23       Impact factor: 2.626

9.  Added Value of Impact Microindentation in the Evaluation of Bone Fragility: A Systematic Review of the Literature.

Authors:  Manuela Schoeb; Neveen A T Hamdy; Frank Malgo; Elizabeth M Winter; Natasha M Appelman-Dijkstra
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-07       Impact factor: 5.555

10.  The Negative Impacts of Acromegaly on Bone Microstructure Not Fully Reversible.

Authors:  Lian Duan; Shengmin Yang; Lin Jie Wang; Yuelun Zhang; Ran Li; Hongbo Yang; Yuxing Zhao; Hanze Du; Xiao Zhai; Fengying Gong; Hui Pan; Huijuan Zhu; Weibo Xia
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-15       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.